Dublin, Aug. 17, 2026 (GLOBE NEWSWIRE) -- The "FDA Inspection Readiness in the AI Era 2026 (Aug 20th - Aug 21st, 2026)" has been added to ResearchAndMarkets.com's offering.
Two-Day Virtual Seminar Helps Pharmaceutical and Biotech Companies Achieve Continuous FDA Inspection Readiness
As the U.S. Food and Drug Administration expands its use of artificial intelligence, data analytics, risk-based facility assessments, and advanced compliance monitoring, pharmaceutical and biotechnology companies face a rapidly evolving inspection environment. Organizations can no longer rely solely on periodic preparation before an anticipated regulatory visit. Continuous FDA inspection readiness is becoming essential for maintaining compliance, protecting product quality, and reducing operational risk.
This intensive two-day virtual seminar will provide pharmaceutical, biotechnology, and life sciences professionals with practical strategies for preparing their organizations for evolving FDA inspection models and data-driven enforcement trends. The program will examine how AI-assisted risk targeting and compliance intelligence may influence facility selection, inspection priorities, and regulatory scrutiny.
Participants will learn how to establish sustainable inspection readiness programs that extend beyond document reviews and pre-inspection activities. The seminar will focus on strengthening quality systems, identifying compliance vulnerabilities, improving cross-functional accountability, and maintaining reliable evidence of ongoing Good Manufacturing Practice compliance.
Key areas of discussion will include FDA inspection readiness, GMP compliance, data integrity, corrective and preventive action effectiveness, and quality culture. Attendees will gain insights into assessing whether quality processes are operating as intended and whether records, investigations, procedures, and supporting data can withstand regulatory review.
The virtual seminar will also address the importance of effective CAPA systems in demonstrating that organizations can identify root causes, implement appropriate corrective actions, evaluate preventive measures, and verify long-term effectiveness. Participants will explore approaches for recognizing recurring issues, addressing systemic weaknesses, and reducing the likelihood that unresolved compliance gaps will result in inspection observations or enforcement action.
Data integrity will remain a central focus throughout the program. Attendees will consider how governance, documentation practices, electronic systems, management oversight, and employee behaviors contribute to the accuracy, completeness, consistency, and reliability of regulated data. The seminar will emphasize the need to detect and remediate data integrity risks before they affect product quality or attract regulatory concern.
In addition, the program will examine how leadership commitment and a strong quality culture support perpetual regulatory readiness. Participants will learn why inspection preparedness must be integrated into routine operations and reinforced through clear responsibilities, effective escalation processes, regular monitoring, and meaningful management review.
By the conclusion of the two-day FDA compliance seminar, participants will be better equipped to evaluate current readiness levels, prioritize remediation activities, and develop sustainable systems that support continuous compliance. The practical guidance presented will help organizations reduce regulatory exposure, improve inspection performance, and respond more effectively to increasing FDA expectations.
This virtual seminar is designed for professionals involved in quality assurance, regulatory affairs, manufacturing, laboratory operations, data governance, validation, compliance, auditing, and executive oversight within pharmaceutical and biotechnology organizations. It will be particularly valuable for teams seeking to modernize FDA inspection preparation while building resilient quality systems capable of meeting emerging regulatory challenges.
With AI-driven risk analysis and advanced monitoring reshaping regulatory oversight, continuous FDA inspection readiness is no longer a short-term initiative. It is a strategic requirement for companies committed to sustained GMP compliance, dependable data, effective quality management, and patient safety.
Who Should Attend:
- Quality Assurance Professionals
- GMP Compliance Teams
- Manufacturing & Operations Leaders
- Validation & CSV Professionals
- Regulatory Affairs Teams
Speaker
Kelly Thomas
For more information about this training visit https://www.researchandmarkets.com/r/wxbwy2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
